Zogenix, Inc. (NASDAQ:ZGNX) EVP Bradley S. Galer bought 1,346 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were purchased at an average price of $36.59 per share, for a total transaction of $49,250.14. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Zogenix, Inc. (NASDAQ:ZGNX) remained flat at $$37.75 during midday trading on Friday. The company had a trading volume of 1,500,000 shares, compared to its average volume of 813,627. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 1 year low of $7.70 and a 1 year high of $42.60.
ZGNX has been the topic of a number of recent analyst reports. Mizuho initiated coverage on shares of Zogenix in a research note on Wednesday, September 6th. They set a “buy” rating and a $28.00 target price on the stock. ValuEngine cut shares of Zogenix from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Stifel Nicolaus restated a “buy” rating and set a $55.00 target price (up previously from $26.00) on shares of Zogenix in a research note on Friday, September 29th. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, William Blair upgraded shares of Zogenix from a “market perform” rating to an “outperform” rating in a research note on Friday, September 29th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $42.67.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.